{"product_id":"bf-002s-sheep-anti-rat-fx1a-serum","title":"Bf-002S Sheep Anti-Rat Fx1A Serum","description":"\u003carticle\u003e\u003cheader\u003e\u003c\/header\u003e\n\u003csection\u003e\n\u003ch2\u003eDescription\u003c\/h2\u003e\n\u003cp\u003eEstablishing a Passive Heymann Nephritis model requires an anti-Fx1A serum that matches the target animal, experimental design and intended level of disease severity. biofargo Bf-002S is a Sheep Anti-Rat Fx1A Serum supplied for the induction of Passive Heymann Nephritis in rats.\u003c\/p\u003e\n\u003cp\u003eThe product is supplied as 25 mL of Anti-Fx1A Serum in 0.02 M phosphate-buffered saline at pH 7.3. One package contains sufficient antibody for 25 rats weighing 175-200 g when used according to the stated directions. Male Sprague-Dawley rats are recommended, while other rat strains have not been tested.\u003c\/p\u003e\n\u003cp\u003ePassive Heymann Nephritis production is dose-dependent. The complete antibody dose must be delivered, and differences between antiserum lots, rat sources and experimental requirements can affect the resulting disease severity. A dose-response study is therefore recommended for each lot before establishing the final experimental conditions.\u003c\/p\u003e\n\u003cp\u003eThe product data describe an initial heterologous phase followed by an autologous phase. Sheep IgG and rat C3 can localize in the glomerular capillaries, proteinuria can develop, and subepithelial immune deposits can be observed. The product has not been validated in mice, and chronic disease has not been verified using this Anti-Fx1A Serum.\u003c\/p\u003e\n\u003c\/section\u003e\n\u003csection\u003e\n\u003ch2\u003eSpecification\u003c\/h2\u003e\n\u003cdiv style=\"max-width: 100%; overflow-x: auto; -webkit-overflow-scrolling: touch;\"\u003e\n\u003ctable\u003e\n\u003ccaption\u003ebiofargo Bf-002S Sheep Anti-Rat Fx1A Serum specifications\u003c\/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\"\u003eParameter\u003c\/th\u003e\n\u003cth scope=\"col\"\u003eSpecification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eBrand\u003c\/th\u003e\n\u003ctd\u003ebiofargo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eCatalog number\u003c\/th\u003e\n\u003ctd\u003eBf-002S\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eProduct name\u003c\/th\u003e\n\u003ctd\u003eSheep Anti-Rat Fx1A Serum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eAlternative name\u003c\/th\u003e\n\u003ctd\u003eAnti-Fx1A Serum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eProduct type\u003c\/th\u003e\n\u003ctd\u003eAntiserum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eHost species\u003c\/th\u003e\n\u003ctd\u003eSheep\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eTarget species\u003c\/th\u003e\n\u003ctd\u003eRat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eFx1A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eApplication\u003c\/th\u003e\n\u003ctd\u003eInduction of Passive Heymann Nephritis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eForm\u003c\/th\u003e\n\u003ctd\u003eSerum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eVolume\u003c\/th\u003e\n\u003ctd\u003e25 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eBuffer\u003c\/th\u003e\n\u003ctd\u003e0.02 M phosphate-buffered saline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003epH\u003c\/th\u003e\n\u003ctd\u003e7.3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C or below\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eFreeze-thaw instruction\u003c\/th\u003e\n\u003ctd\u003eAvoid repeated freeze-thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003ePreparation before use\u003c\/th\u003e\n\u003ctd\u003eCentrifuge at 3,000 rpm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eAnimal coverage\u003c\/th\u003e\n\u003ctd\u003eSufficient for 25 rats weighing 175-200 g when used according to the stated directions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eRecommended rat strain\u003c\/th\u003e\n\u003ctd\u003eMale Sprague-Dawley rats\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eOther rat strains\u003c\/th\u003e\n\u003ctd\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eMouse validation\u003c\/th\u003e\n\u003ctd\u003eNot validated in mice\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth scope=\"row\"\u003eChronic disease verification\u003c\/th\u003e\n\u003ctd\u003eChronic disease has not been verified using this Anti-Fx1A Serum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection\u003e\n\u003ch2\u003eFeatures\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDefined model application:\u003c\/strong\u003e Supplied for the induction of Passive Heymann Nephritis in rats.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies-specific product:\u003c\/strong\u003e Sheep antiserum directed against rat Fx1A.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e25 mL package:\u003c\/strong\u003e Contains sufficient antibody for 25 rats weighing 175-200 g when used according to the stated directions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecified formulation:\u003c\/strong\u003e Supplied in 0.02 M phosphate-buffered saline at pH 7.3.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFrozen storage:\u003c\/strong\u003e Store at -20°C or below and avoid repeated freeze-thaw cycles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePre-use preparation:\u003c\/strong\u003e Centrifuge the Anti-Fx1A Serum at 3,000 rpm before use.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecommended animals:\u003c\/strong\u003e Male Sprague-Dawley rats are recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDose-dependent response:\u003c\/strong\u003e Complete delivery of the antibody dose is important for disease production.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLot-specific study design:\u003c\/strong\u003e A dose-response study is recommended to establish the desired disease severity for each antiserum lot.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/section\u003e\n\u003csection\u003e\n\u003ch2\u003eApplication\u003c\/h2\u003e\n\u003cp\u003ebiofargo Bf-002S Sheep Anti-Rat Fx1A Serum is supplied for the induction of Passive Heymann Nephritis in rats.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePassive Heymann Nephritis induction\u003c\/li\u003e\n\u003cli\u003eAnti-Fx1A rat model establishment\u003c\/li\u003e\n\u003cli\u003eProteinuria assessment in the Passive Heymann Nephritis model\u003c\/li\u003e\n\u003cli\u003eGlomerular sheep IgG deposition assessment\u003c\/li\u003e\n\u003cli\u003eGlomerular rat C3 localization assessment\u003c\/li\u003e\n\u003cli\u003eSubepithelial immune-deposit assessment\u003c\/li\u003e\n\u003cli\u003eGlomerular basement membrane change assessment\u003c\/li\u003e\n\u003cli\u003eMesangial matrix change assessment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eHeterologous Disease Phase\u003c\/h3\u003e\n\u003cp\u003eFaint to moderate deposits of heterologous sheep IgG can become detectable in the glomerular capillaries by immunofluorescence within minutes after a single administration of Anti-Fx1A Serum. The intensity and granularity of these deposits can increase during the following 3-5 days. Rat C3 can also localize in a granular pattern, and proteinuria can develop after approximately 5 days.\u003c\/p\u003e\n\u003ch3\u003eAutologous Disease Phase\u003c\/h3\u003e\n\u003cp\u003eThe autologous phase can become noticeable 7-10 days after administration of the Anti-Fx1A antibody. The product data describe increased proteinuria and glomerular localization of rat IgG in a string-of-pearls pattern by immunohistochemistry. Subepithelial immune deposits can be observed by electron microscopy.\u003c\/p\u003e\n\u003cp\u003eBy approximately 3 weeks, proteinuria can reach 100-200 mg per 24 hours when measured using the Bradford assay. During the first few weeks, glomeruli may appear unremarkable by routine light microscopy. The data sheet describes possible progression to thickened basement membranes, increased mesangial matrix and possible sclerosis after approximately 3 months. Chronic disease, however, has not been verified using this Anti-Fx1A Serum.\u003c\/p\u003e\n\u003c\/section\u003e\n\u003csection\u003e\n\u003ch2\u003eFAQ\u003c\/h2\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat is biofargo Bf-002S?\u003c\/summary\u003e\n\u003cp\u003eBf-002S is a Sheep Anti-Rat Fx1A Serum supplied for the induction of Passive Heymann Nephritis in rats.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat is Sheep Anti-Rat Fx1A Serum used for?\u003c\/summary\u003e\n\u003cp\u003eThe serum is used to induce a Passive Heymann Nephritis model in rats.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat is the catalog number of the Anti-Fx1A Serum?\u003c\/summary\u003e\n\u003cp\u003eThe biofargo catalog number is Bf-002S.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat is the product volume?\u003c\/summary\u003e\n\u003cp\u003eBf-002S is supplied as 25 mL of Anti-Fx1A Serum.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eHow many rats can be studied with one 25 mL package?\u003c\/summary\u003e\n\u003cp\u003eOne package contains sufficient antibody to induce Passive Heymann Nephritis in 25 rats weighing 175-200 g when used according to the stated directions.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat rat strain is recommended?\u003c\/summary\u003e\n\u003cp\u003eMale Sprague-Dawley rats are recommended. Other rat strains were not tested in the referenced product data.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eCan Bf-002S Anti-Fx1A Serum be used in mice?\u003c\/summary\u003e\n\u003cp\u003eThe product has not been validated in mice.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat buffer is used for Bf-002S?\u003c\/summary\u003e\n\u003cp\u003eThe Anti-Fx1A Serum is supplied in 0.02 M phosphate-buffered saline at pH 7.3.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eHow should the Anti-Fx1A Serum be stored?\u003c\/summary\u003e\n\u003cp\u003eStore the serum at -20°C or below and avoid repeated freeze-thaw cycles.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eDoes the serum require preparation before use?\u003c\/summary\u003e\n\u003cp\u003eYes. The product data instruct users to centrifuge the serum at 3,000 rpm before use.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat is the stated dose for Passive Heymann Nephritis induction?\u003c\/summary\u003e\n\u003cp\u003eThe stated dose is 0.4 mL of Anti-Fx1A Serum per 100 g of body weight.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eHow is the serum administered according to the data sheet?\u003c\/summary\u003e\n\u003cp\u003eThe data sheet describes administration into a tail vein over a period of 15-30 seconds after the rat has been anesthetized.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhy is complete dose delivery important?\u003c\/summary\u003e\n\u003cp\u003ePassive Heymann Nephritis production is dose-dependent. The product data state that the complete antibody dose must be delivered.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhy is a dose-response study recommended?\u003c\/summary\u003e\n\u003cp\u003eAntiserum lots, rat sources and experimental requirements can vary. A dose-response study is recommended to establish the desired disease severity for each lot.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhen can proteinuria develop in the Passive Heymann Nephritis model?\u003c\/summary\u003e\n\u003cp\u003eThe product data state that proteinuria can develop after approximately 5 days during the heterologous phase. By approximately 3 weeks, proteinuria can reach 100-200 mg per 24 hours when measured using the Bradford assay.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat immune-deposit pattern is described in the autologous phase?\u003c\/summary\u003e\n\u003cp\u003eRat IgG can localize in the glomeruli in a string-of-pearls pattern by immunohistochemistry. Subepithelial immune deposits can also be observed by electron microscopy.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eHas chronic Passive Heymann Nephritis been verified with Bf-002S?\u003c\/summary\u003e\n\u003cp\u003eNo. Chronic disease has not been verified using this Anti-Fx1A Serum.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003c\/section\u003e\n\u003c\/article\u003e","brand":"Biofargo","offers":[{"title":"25ml","offer_id":53105136959669,"sku":"BF-002S","price":850.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0521\/5312\/2997\/files\/Bf-002S_Sheep_Anti-Rat_Fx1A_Serum.png?v=1787882435","url":"https:\/\/biofargo.com\/products\/bf-002s-sheep-anti-rat-fx1a-serum","provider":"Biofargo","version":"1.0","type":"link"}